...
search icon
rlmd-img

Relmada Therapeutics Inc Share Price

RLMD
NAQ
$3.72
-$0.18
(-4.62%)
1D
Industry: Pharmaceuticals Sector: Health Care

Relmada Therapeutics Inc Analyst Forecast

Relmada Therapeutics Inc Share Price Chart

Relmada Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$272.80M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
198.89K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.83
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.24 L
$5.12 H
$3.72

About Relmada Therapeutics Inc, Common Stock

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida. more

Industry: PharmaceuticalsSector: Health Care

Relmada Therapeutics Inc Stock Returns

Time FrameRLMDSectorS&P500
1-Week Return-4.12%-0.03%-1.38%
1-Month Return-8.37%0.59%-1.81%
3-Month Return-4.12%3.23%1.38%
6-Month Return554.7%18.29%5.68%
1-Year Return1032.08%7.71%11.74%
3-Year Return-0.53%18.03%65.15%
5-Year Return-90.33%35.78%73.68%
10-Year Return-39.61%140.42%260.03%

Relmada Therapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue3.75K1.26K---[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":33.53,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(3.75K)(1.26K)---[{"date":"2020-12-31","value":-375200,"profit":false},{"date":"2021-12-31","value":-125800,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses60.84M125.70M161.25M103.70M83.89M[{"date":"2020-12-31","value":37.73,"profit":true},{"date":"2021-12-31","value":77.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":64.31,"profit":true},{"date":"2024-12-31","value":52.03,"profit":true}]
Operating Income(60.84M)(125.70M)(161.25M)(103.70M)(83.89M)[{"date":"2020-12-31","value":-6083867300,"profit":false},{"date":"2021-12-31","value":-12570349200,"profit":false},{"date":"2022-12-31","value":-16124900000,"profit":false},{"date":"2023-12-31","value":-10370200000,"profit":false},{"date":"2024-12-31","value":-8389103600,"profit":false}]
Total Non-Operating Income/Expense2.78M1.15M6.87M10.06M7.44M[{"date":"2020-12-31","value":27.64,"profit":true},{"date":"2021-12-31","value":11.44,"profit":true},{"date":"2022-12-31","value":68.23,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":73.96,"profit":true}]
Pre-Tax Income(59.46M)(125.75M)(157.04M)(98.79M)(79.98M)[{"date":"2020-12-31","value":-5945639400,"profit":false},{"date":"2021-12-31","value":-12575180900,"profit":false},{"date":"2022-12-31","value":-15704300000,"profit":false},{"date":"2023-12-31","value":-9879200000,"profit":false},{"date":"2024-12-31","value":-7997935400,"profit":false}]
Income Taxes(1.38M)48.32K(2.66M)(103.70K)-[{"date":"2020-12-31","value":-2860.28,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-5503.24,"profit":false},{"date":"2023-12-31","value":-214.63,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(58.07M)(125.80M)(154.38M)(98.69M)-[{"date":"2020-12-31","value":-5807439400,"profit":false},{"date":"2021-12-31","value":-12580012600,"profit":false},{"date":"2022-12-31","value":-15438400000,"profit":false},{"date":"2023-12-31","value":-9868829800,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(59.46M)(125.75M)(157.04M)(98.79M)(79.98M)[{"date":"2020-12-31","value":-5945639400,"profit":false},{"date":"2021-12-31","value":-12575180900,"profit":false},{"date":"2022-12-31","value":-15704382300,"profit":false},{"date":"2023-12-31","value":-9879174600,"profit":false},{"date":"2024-12-31","value":-7997935400,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(59.46M)(125.75M)(157.04M)(98.79M)(79.98M)[{"date":"2020-12-31","value":-5945639400,"profit":false},{"date":"2021-12-31","value":-12575180900,"profit":false},{"date":"2022-12-31","value":-15704300000,"profit":false},{"date":"2023-12-31","value":-9879200000,"profit":false},{"date":"2024-12-31","value":-7997935400,"profit":false}]
EPS (Diluted)(3.81)(7.14)(5.45)(3.28)(2.65)[{"date":"2020-12-31","value":-381,"profit":false},{"date":"2021-12-31","value":-714,"profit":false},{"date":"2022-12-31","value":-545,"profit":false},{"date":"2023-12-31","value":-328,"profit":false},{"date":"2024-12-31","value":-265,"profit":false}]

Relmada Therapeutics Inc Ratios

Relmada Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

RLMD
Cash Ratio 2.68
Current Ratio 2.86

Relmada Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RLMD
ROA (LTM) -102.41%
ROE (LTM) -196.79%

Relmada Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RLMD
Debt Ratio Lower is generally better. Negative is bad. 0.36
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.64

Relmada Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RLMD
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 28.82
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.54

FAQs

What is Relmada Therapeutics Inc share price today?

Relmada Therapeutics Inc (RLMD) share price today is $3.72

Can Indians buy Relmada Therapeutics Inc shares?

Yes, Indians can buy shares of Relmada Therapeutics Inc (RLMD) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RLMD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Relmada Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Relmada Therapeutics Inc (RLMD) via the Vested app. You can start investing in Relmada Therapeutics Inc (RLMD) with a minimum investment of $1.

How to invest in Relmada Therapeutics Inc shares from India?

You can invest in shares of Relmada Therapeutics Inc (RLMD) via Vested in three simple steps:

  • Click on Sign Up or Invest in RLMD stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Relmada Therapeutics Inc shares
What is Relmada Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Relmada Therapeutics Inc (RLMD) is $5.12. The 52-week low price of Relmada Therapeutics Inc (RLMD) is $0.24.

What is Relmada Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Relmada Therapeutics Inc (RLMD) is

What is Relmada Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Relmada Therapeutics Inc (RLMD) is 28.82

What is Relmada Therapeutics Inc dividend yield?

The dividend yield of Relmada Therapeutics Inc (RLMD) is 0.00%

What is the Market Cap of Relmada Therapeutics Inc?

The market capitalization of Relmada Therapeutics Inc (RLMD) is $272.80M

What is Relmada Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Relmada Therapeutics Inc is RLMD

How Can Investors Use Relmada Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Relmada Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Relmada Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Relmada Therapeutics Inc shares for Indian investors?

When investing in Relmada Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Relmada Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Relmada Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Relmada Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Relmada Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top